WELLBUTRIN WITHDRAWAL SYMPTOMS  / Weaning off  Wellbutrin NATURALLY & SUCCESSFULLY

WELLBUTRIN SIDE EFFECTS MAY INCLUDE: 

aggression, anxiety, balance issues , blurred vision, brain zaps, concentration impairment, constipation, crying spells, depersonalization, diarrhea, dizziness. electric shock sensations, fatigue, flatulence, flu-like symptoms, hallucinations, hostility, highly emotional, indigestion, irritability, impaired speech, insomnia, jumpy nerves, lack of coordination, lethargy, migraine headaches / increased headaches, nausea, nervousness, over-reacting to situations, paranoia, repetitive thoughts or songs, sensory & sleep disturbances, severe internal restlessness (akathisia), stomach cramps, tremors, tinnitus (ear ringing or buzzing), tingling sensations, troubling thoughts, visual hallucinations / illusions, vivid dreams, speech or visual changes, worsened depression 

WELLBUTRIN ADVERSE REACTIONS MAY INCLUDE: per PDR   

Severe: suicidal ideation, seizures, anaphylactoid reactions, coma, stroke, myocardial infarction, GI perforation, GI bleeding, bronchospasm, Tourette's syndrome, pulmonary embolism, AV block, ocular hypertension, pancreatitis, exfoliative dermatitis, SIADH, pancytopenia, rhabdomyolysis, erythema multiforme, Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), anaphylactic shock, serum sickness, Stevens-Johnson syndrome, angioedema, tardive dyskinesia, akinesia, hearing loss, neonatal abstinence syndrome, serotonin syndrome

Moderate: 

constipation, migraine, blurred vision, sinus tachycardia, confusion, palpitations, hostility, hypertension, chest pain (unspecified), impotence (erectile dysfunction), memory impairment, hot flashes, hypotension, dysphoria, dysphagia, oral ulceration, vaginal bleeding, urinary retention, akathisia, pseudoparkinsonism, euphoria, dysarthria, psychosis, depression, peripheral vasodilation, orthostatic hypotension, jaundice, elevated hepatic enzymes, teeth grinding (bruxism), glossitis, testicular swelling, ejaculation dysfunction, dyspnea, peripheral edema, hypertonia, aphasia, neuropathic pain, EEG changes, amnesia, phlebitis, colitis, dyspareunia, dysuria, cystitis, ataxia, mania, hallucinations, myoclonia, edema, stomatitis, dystonic reaction, dyskinesia, delirium, impulse control symptoms, esophagitis, hepatitis, hyperglycemia, hypoglycemia, glycosuria, hyponatremia, leukopenia, lymphadenopathy, thrombocytopenia, anemia, myasthenia, urinary incontinence

Mild: insomnia, headache, agitation, xerostomia, weight loss, vomiting, nausea, hyperhidrosis, tremor, anorexia, weight gain, pharyngitis, rhinitis, dizziness, abdominal pain, infection, anxiety, rash, diarrhea, flatulence, myalgia, tinnitus, arthralgia, sinusitis, fatigue, increased urinary frequency, menstrual irregularity, flushing, dysgeusia, pruritus, asthenia, cough, appetite stimulation, hypersalivation, dyspepsia, libido decrease, drowsiness, irritability, diplopia, restlessness, paresthesias, dysmenorrhea, urticaria, xerosis, fever, epistaxis, urinary urgency, syncope, chills, vertigo, paranoia, emotional lability, xerophthalmia, gastroesophageal reflux, polydipsia, gingivitis, vaginal irritation, gynecomastia, acne vulgaris, photosensitivity, ecchymosis, back pain, muscle cramps, dental pain, polyuria, hyperkinesis, pallor, maculopapular rash, hirsutism, malaise, hair discoloration, drug-induced body odor, lethargy, libido increase, alopecia, influenza, nasal congestion, nocturia, mydriasis, leukocytosis

WELLBUTRIN BOXED WARNINGS: per PDR    

Children, suicidal ideation

The safety and efficacy of bupropion for smoking cessation is not established in children or adolescents. Children 6 years and older with a major depressive episode or attention-deficit hyperactivity disorder (ADHD) have been studied in clinical trials of bupropion, but data regarding pediatric safety are limited. When bupropion is used for the treatment of ADHD in pediatrics, careful screening and monitoring is recommended by the American Heart Association. In October 2004, the FDA directed manufacturers of all antidepressants to include a boxed warning detailing the risk of suicide in pediatric patients. The risk of suicidality for these drugs was identified in a pooled analysis of 24 placebo-controlled trials (n = 4400) lasting up to 16 weeks in pediatric patients with major depressive disorder (MDD), obsessive compulsive disorder (OCD), or other psychiatric disorders. The analysis showed a greater risk of suicidality during the first few months of treatment in those receiving antidepressants. The average risk of such events was 4% on drug and 2% for placebo; however, no suicides occurred. Pooled analysis of short-term clinical trials during early phase treatment with antidepressants in young adults (18 to 24 years) also showed an increased risk of suicidal thinking and behavioral changes. The clinical need for an antidepressant in pediatrics or young adults for any use must be weighed against the risk of increased suicidality; patients who are started on therapy should be observed closely for clinical worsening, suicidality, or behavioral changes, particularly within the first few months of starting therapy or during dose adjustments. It is unknown if the suicidality risk in children and young adults extends to longer-term therapy. The possibility of a suicide attempt is inherent in any patient with depressive symptoms, whether these occur in a primary depressive episode or in association with another primary disorder such as OCD.  In patients who exhibit adverse changes in symptoms, worsening of depressive symptoms, or suicidality, a decision should be made to change or discontinue treatment. If discontinuing bupropion, the medication should be tapered as rapidly as possible, but with recognition that discontinuing treatment abruptly can also cause adverse symptoms. Bupropion should be prescribed in the smallest quantity consistent with good patient management in order to reduce the risk of overdose.

top of page